Development of Piperazine- and Oxazine-Linked Pyrimidines as p65 Subunit Binders of NF-κB in Human Breast Cancer Cells.
Alamar Blue assay
NF–κB
apoptosis assay
molecular docking
oxazines
piperazines
pyrimidines
western blot
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
06 Oct 2023
06 Oct 2023
Historique:
received:
27
06
2023
revised:
01
09
2023
accepted:
12
09
2023
medline:
28
10
2023
pubmed:
28
10
2023
entrez:
28
10
2023
Statut:
epublish
Résumé
Nuclear factor kappa B (NF-κB) is a potential therapeutic target in breast cancer. In the current study, a new class of oxazine- and piperazine-linked pyrimidines was developed as inhibitors of NF-κB, overcoming the complexity of the oxazine structure found in nature and enabling synthesis under laboratory conditions. Among the series of synthesized and tested oxazine-pyrimidine and piperazine-pyrimidine derivatives, compounds
Identifiants
pubmed: 37893090
pii: biomedicines11102716
doi: 10.3390/biomedicines11102716
pmc: PMC10604619
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Department of Science and Technology
ID : CESEM-637
Références
Molecules. 2021 Feb 03;26(4):
pubmed: 33546391
Int J Mol Sci. 2020 Mar 13;21(6):
pubmed: 32183020
Front Pharmacol. 2018 Nov 05;9:1125
pubmed: 30455641
Med Chem. 2023;19(6):578-585
pubmed: 36573048
J Enzyme Inhib Med Chem. 2021 Dec;36(1):1165-1197
pubmed: 34080510
J Med Chem. 2021 Jul 22;64(14):10001-10018
pubmed: 34212719
Biochimie. 2011 May;93(5):899-908
pubmed: 21295107
Biotechnol Rep (Amst). 2020 Feb 19;25:e00438
pubmed: 32140443
Eur J Pharm Sci. 2020 Nov 1;154:105493
pubmed: 32730846
Bioorg Med Chem Lett. 2008 Jan 15;18(2):653-6
pubmed: 18054489
Int J Biochem Cell Biol. 2019 Apr;109:76-81
pubmed: 30772480
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Int Immunopharmacol. 2012 Feb;12(2):368-77
pubmed: 22197802
Cancer Epidemiol. 2013 Aug;37(4):512-7
pubmed: 23545383
J Comput Chem. 2007 Apr 30;28(6):1145-52
pubmed: 17274016
Molecules. 2022 Apr 29;27(9):
pubmed: 35566199
Cell. 2017 Jan 12;168(1-2):37-57
pubmed: 28086098
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Mediators Inflamm. 2022 Jan 29;2022:2567150
pubmed: 35132306
Front Oncol. 2020 Apr 22;10:584
pubmed: 32391269
Nat Rev Drug Discov. 2009 Jan;8(1):33-40
pubmed: 19116625
Biochem Pharmacol. 2010 May 1;79(9):1272-80
pubmed: 20067776
Science. 1994 Aug 12;265(5174):956-9
pubmed: 8052854
Sci Rep. 2016 Apr 13;6:24172
pubmed: 27072064
Science. 1997 Jan 24;275(5299):523-7
pubmed: 8999795
CA Cancer J Clin. 2022 Nov;72(6):524-541
pubmed: 36190501
Eur J Med Chem. 2022 Dec 5;243:114704
pubmed: 36095992
J Biol Chem. 2002 Mar 29;277(13):11345-51
pubmed: 11801595
PLoS One. 2016 Sep 29;11(9):e0163209
pubmed: 27685808
Br J Pharmacol. 1971 Nov;43(3):649-57
pubmed: 5003353
RSC Adv. 2021 Apr 23;11(25):15213-15230
pubmed: 35424074
Science. 1995 Dec 22;270(5244):2017-9
pubmed: 8533099
Cold Spring Harb Perspect Biol. 2009 Oct;1(4):a000034
pubmed: 20066092
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708302
Eur J Med Chem. 2020 Jul 15;198:112366
pubmed: 32371335
Cell. 1986 Aug 29;46(5):705-16
pubmed: 3091258